MiNK Therapeutics announces clinical data of allogeneic iNKT cells

MiNK Therapeutics presented data at the American Association of Cancer Research annual meeting, demonstrating the clinical benefit of allo-iNKTs, agenT-797, alone and in combination with anti-PD-1 in patients with refractory non-small cell lung cancer, testicular, and gastric cancers. In a phase 1/2 trial, patients received a single infusion of agenT-797, alone or in combination with pembro or nivo, without lymphodepletion. Patients were heavily pretreated with a median of 4 prior lines of therapy and were unresponsive to prior anti-PD-1 therapy. The results showed that agenT-797 promoted durable responses, including a partial response and tumor reduction of greater than42% which was ongoing at 9 months in a patient with metastatic gastric cancer who had no response to prior treatment with pembro or nivo plus FOLFOX. Additionally, durable disease stabilization and biomarker responses were observed in NSCLC and testicular cancers refractory to anti-PD-1. AgenT-797 was persistent and detectable in the periphery for greater than ~8 weeks and tolerable up to 1000×106 cells, with no neurotoxicity, dose-limiting toxicities, or severe cytokine release syndrome. Administration of agenT-797 induced a systemic and local anti-tumor response, driving immune cell infiltration into tumors and promoting immune cell activation. MiNK Therapeutics will further evaluate agenT-797 through phase 1/2 expansion trials in combination with standard of care agents with or without botensilimab in relapsed/refractory NSCLC, testicular cancer, and in 2L gastric cancer through a phase 1/2 investigator sponsored trial led by Dr. Yelena Janjigian, Chief Gastrointestinal Oncology, Memorial Sloan Kettering Cancer Center.